PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
PacBio (NASDAQ: PACB) said management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 11:30 AM ET in New York.
A live webcast will be available on the company investor site at investor.pacificbiosciences.com, with a replay accessible for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
On the day this news was published, PACB declined 2.93%, reflecting a moderate negative market reaction. This price movement removed approximately $21M from the company's valuation, bringing the market cap to $691M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While PACB traded down 2.47%, several peers like DCTH (+4.53%) and RXST (+4.22%) were up, indicating stock-specific weakness rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 28 | Investor conference | Neutral | -2.9% | Announcement of participation in Piper Sandler healthcare conference with webcast access. |
| Nov 13 | Investor conferences | Neutral | -1.2% | Management scheduled for multiple investor conferences and fireside chats in November. |
| Nov 05 | Earnings update | Neutral | -4.3% | Q3 2025 results with lower revenue but improved margins and lower operating expenses. |
| Nov 05 | Clinical study data | Positive | -4.3% | HiFi Solves consortium study showing strong detection of pathogenic variants with HiFi genomes. |
| Nov 04 | Regulatory approval | Positive | -10.7% | First clinical long-read sequencing regulatory approval in China via Sequel II CNDx system. |
Over the last five news events, PACB shares moved lower after all announcements, including positive clinical and regulatory updates, indicating a pattern of negative price reactions to neutral or positive news.
This announcement adds to a series of visibility-focused events for PacBio, following multiple investor conference presentations in mid-November 2025. Earlier in the month, the company reported Q3 2025 results with revenue of $38.4M and improved non-GAAP gross margin of 42%, alongside reduced operating expenses. Clinical and regulatory milestones included a major HiFi Solves consortium study and NMPA Class III approval for the Sequel II CNDx system in China. Despite these developments, PACB’s shares declined after each of these prior announcements.
Market Pulse Summary
This announcement highlights PacBio management’s participation in a Piper Sandler healthcare conference, with a live webcast and at least 30 days of replay access, adding to recent investor outreach activity. In the weeks prior, the company reported Q3 2025 financials and notable clinical and regulatory milestones. Investors may focus on any incremental commentary delivered at the event regarding revenue trends, margin progress, cash balances, and the commercialization path for its sequencing platforms.
AI-generated analysis. Not financial advice.
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY.
A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
FAQ
When is PacBio (PACB) presenting at the Piper Sandler 37th Annual Healthcare Conference?
How can investors watch the PacBio (PACB) Piper Sandler fireside chat on December 3, 2025?
Will a replay of the PacBio (PACB) Piper Sandler presentation be available after December 3, 2025?
What topic will PacBio (PACB) management cover at the December 3, 2025 fireside chat?
Is PacBio (PACB) participating in-person at the Piper Sandler conference on December 3, 2025?
Where can I find the PacBio (PACB) webcast link for the Piper Sandler conference?
